BiondVax Pharmaceuticals, Cytovance Biologics prepare flu vaccine for Phase III trials
"I am happy and proud of this new strategic relationship with Cytovance Biologics Inc., a U.S. leader in contract manufacturing with a significant track record in the production of clinical materials. This is a key development for BiondVax that will play a major role in accelerating the clinical development and large-scale manufacture of our universal flu vaccine, M-001. I believe that our vaccine will improve the lives of the millions of individuals who currently suffer and some of which die every year, from Influenza and its complications,” BiondVax Chief Operations OFficer Shimon Hassin said.
Phase III clinical batches will be manufactured by the end of 2016 in order for BiondVax to conduct studies in 2017-2018.
"Cytovance's state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for BiondVax," Cytovance CEO and President Darren Head said.